Actively Recruiting
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-09-24
40
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
CONDITIONS
Official Title
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathology confirmed limited-stage small cell lung cancer
- ECOG performance status score between 0 and 2
- Good organ function without blood transfusions or hematopoietic stimulating factors within 14 days before examination
- Suitable for treatment with Trilaciclib combined with etoposide plus cisplatin or carboplatin
- Able to understand and sign informed consent
You will not qualify if you...
- Brain metastases with symptoms requiring local radiotherapy or hormone therapy
- Active infections requiring systemic treatment
- Active, known, or suspected autoimmune disease or history of autoimmune disease
- Presence of other tumors
- Current or past clinically significant unstable medical conditions that may affect safety or study results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
X
Xinrong Lian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here